Drug Repurposing Market Overview
The Drug Repurposing Market covers the development and commercial use of existing medicines for new therapeutic purposes. Instead of discovering a completely new drug from the beginning, drug repurposing involves identifying additional applications for compounds that have already undergone significant research, safety evaluation, or clinical use. This approach can help pharmaceutical companies reduce development risks, shorten research timelines, and address unmet medical needs across areas such as oncology, neurological disorders, rare diseases, infectious diseases, and cardiovascular conditions. According to Market Research Future, the global market was valued at approximately USD 39.2 billion in 2025 and is projected to reach USD 52.8 billion by 2035, expanding at a CAGR of 3.1% during the forecast period.
Get Free Sample PDF Brochure:
https://www.marketresearchfuture.com/sample_request/22086
Market Drivers
Growing Need to Reduce Drug Development Costs:
Developing a completely new medicine can require substantial investment, extensive clinical testing, and many years of research. Drug repurposing offers a more efficient route because developers can build on existing information about a drug’s pharmacology, safety profile, manufacturing process, and clinical history. This cost and time advantage is encouraging pharmaceutical companies and biotechnology firms to explore additional indications for established medicines.
Increasing Prevalence of Chronic and Complex Diseases:
The global burden of cancer, neurological disorders, autoimmune diseases, cardiovascular conditions, and other chronic illnesses continues to increase. At the same time, many diseases still have limited treatment options. Repurposing existing medicines provides researchers with another pathway for identifying potential therapies, particularly for diseases where conventional drug discovery has produced limited results.
Advances in Artificial Intelligence and Computational Drug Discovery:
The development of artificial intelligence, machine learning, network pharmacology, and large-scale biological databases is changing how researchers identify repurposing opportunities. Modern computational platforms can analyze relationships between drugs, molecular targets, genes, pathways, and diseases much faster than traditional screening approaches. These technologies are helping researchers prioritize promising drug-indication combinations for further laboratory and clinical investigation.
Rising Pharmaceutical R&D Efficiency Requirements:
Pharmaceutical companies are under continuous pressure to improve research productivity while managing rising development costs. Repurposing established compounds can complement conventional R&D pipelines by providing additional opportunities from existing drug portfolios. The approach can also help companies explore new indications before products lose commercial momentum.
Growing Interest in Rare and Orphan Diseases:
Rare diseases often have small patient populations, making traditional drug development commercially challenging. Repurposing medicines with established safety information can make research into these conditions more attractive. Regulatory incentives and orphan-drug programs in major markets are also encouraging companies to investigate existing compounds for rare-disease applications.
Increasing Collaboration Across the Pharmaceutical Ecosystem:
Drug repurposing increasingly involves partnerships between pharmaceutical companies, biotechnology firms, academic institutions, research organizations, data companies, and contract research organizations. These collaborations combine clinical knowledge, biological datasets, computational capabilities, and drug-development expertise, helping accelerate the identification and validation of promising candidates.
Market Challenges
Limited Intellectual Property Protection:
One of the major challenges associated with drug repurposing is protecting commercial returns. Many drugs considered for new indications have already lost or are approaching the end of their original patent protection. Although companies may obtain patents covering new uses, formulations, or dosing strategies, these forms of protection can be narrower than original composition-of-matter patents.
Clinical Validation Requirements:
Even when an existing drug has a well-established safety history, demonstrating that it works effectively for a new disease generally requires appropriate clinical evidence. Developers may still need to conduct clinical trials to establish efficacy, optimal dosage, patient selection, and long-term outcomes for the new indication.
Regulatory Complexity:
Regulatory requirements for repurposed medicines can vary across countries. A development strategy that benefits from an abbreviated pathway in one market may require additional studies or documentation elsewhere. Differences in regulatory procedures can increase development complexity and delay international commercialization.
Uncertainty Around Reimbursement:
Regulatory approval does not automatically guarantee favorable reimbursement. Healthcare payers may evaluate a repurposed therapy based on clinical benefits, cost-effectiveness, treatment alternatives, and the strength of supporting evidence. This can create uncertainty for companies investing in new indications.
Shortage of Specialized Expertise:
Successful repurposing programs require expertise spanning drug discovery, computational biology, clinical research, regulatory affairs, intellectual property, and commercial strategy. Smaller organizations may face difficulties accessing all of these capabilities internally.
Competition from New Drug Discovery Technologies:
Although repurposing can reduce development risk, it competes with innovative approaches such as biologics, gene therapies, cell therapies, and novel small-molecule discovery. Some diseases may require entirely new therapeutic mechanisms that cannot be addressed effectively through existing medicines.
Browse In-depth Market Research Report on Drug Repurposing Market:
https://www.marketresearchfuture.com/reports/drug-repurposing-market-22086
Market Segmentation
By Type:
Disease-Centric:
Disease-centric repurposing starts with a specific medical condition and searches for existing medicines that could potentially address its biological mechanisms. This approach is useful when researchers have identified significant unmet needs but lack sufficient treatment options.
Target-Centric:
Target-centric repurposing focuses on biological targets such as proteins, receptors, enzymes, genes, or signaling pathways. Researchers identify drugs that interact with a particular target and evaluate whether those interactions could be useful in another disease.
Drug-Centric:
Drug-centric repurposing begins with an existing medicine and investigates additional diseases or biological pathways that could potentially benefit from its pharmacological properties.
By Therapeutic Area:
Oncology:
Cancer is an important area for drug repurposing because numerous existing medicines have biological effects that may be relevant to tumor growth, immune responses, cellular signaling, and cancer metabolism. Repurposing can also be explored in combination with established cancer treatments.
Central Nervous System Disorders:
Neurological and neurodegenerative diseases represent an attractive area for repurposing because conventional drug discovery in these conditions can be particularly challenging. Researchers are evaluating existing medicines for potential applications in conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and other neurological disorders.
Rare and Orphan Diseases:
Drug repurposing provides an opportunity to investigate established compounds for diseases with limited treatment choices. Regulatory incentives and the high level of unmet medical need are supporting research activity in this segment.
Infectious Diseases:
Existing medicines are being evaluated for potential activity against infectious diseases, particularly when rapid therapeutic development is required or when resistance limits conventional treatment options.
Cardiovascular Diseases:
Researchers are exploring established cardiovascular and other drug classes for additional applications involving heart disease, vascular conditions, and related metabolic disorders.
Other Therapeutic Areas:
This category includes autoimmune disorders, metabolic diseases, respiratory conditions, dermatological disorders, and other areas where existing medicines may have previously unrecognized therapeutic potential.
By Drug Molecules:
Small Molecules:
Small-molecule medicines represent a major part of drug repurposing because many have well-documented pharmacological and safety characteristics. Their established manufacturing processes and oral formulations can also support development for additional indications.
Biologics:
Biological medicines are gaining attention in repurposing research as advances in biotechnology and analytical techniques make it easier to investigate their activity across different diseases.
By Therapeutic Approach:
Same Therapeutic Area:
This approach involves finding an additional indication for an existing drug within the same broad medical field. Because the mechanism of action and clinical experience may already be well understood, development can sometimes be more straightforward.
Different Therapeutic Area:
This strategy involves applying an established medicine to a completely different disease category. It can create significant opportunities but often requires deeper investigation into the drug’s mechanism and clinical relevance.
By End User:
Pharmaceutical and Biotechnology Companies:
Large pharmaceutical companies and biotechnology firms are major participants in drug repurposing. These organizations can leverage existing research assets and development infrastructure to explore new therapeutic opportunities.
Contract Research Organizations:
CROs support pharmaceutical and biotechnology companies with laboratory research, preclinical testing, clinical trials, data analysis, and regulatory services.
Academic and Research Institutes:
Universities and research organizations contribute significantly to early-stage drug repurposing through laboratory studies, computational research, clinical investigations, and collaborations with industry.
Other Organizations:
Nonprofit groups, government agencies, healthcare institutions, and disease-focused foundations may also support repurposing programs, particularly for rare diseases and public-health priorities.
Regional Insights
North America:
North America represents a leading market for drug repurposing, supported by a strong pharmaceutical industry, extensive research infrastructure, advanced computational capabilities, and established regulatory pathways. The U.S. accounts for a substantial share of regional activity due to its large pharmaceutical R&D ecosystem and access to clinical and real-world healthcare data. Market Research Future identifies North America as the leading regional market.
Europe:
Europe has a strong foundation in pharmaceutical research, academic collaboration, and translational medicine. Countries such as Germany, France, the UK, Italy, and Spain are contributing to drug repurposing research through pharmaceutical companies, universities, hospitals, and research networks. European regulatory initiatives also support the development of medicines for new indications.
Asia-Pacific:
Asia-Pacific is expected to offer significant growth opportunities as pharmaceutical R&D activity, clinical-trial capabilities, healthcare investment, and biotechnology infrastructure expand. China, India, Japan, and South Korea are increasingly important markets for pharmaceutical research and development. The region is also attractive because of its growing pool of scientific talent and cost-competitive research capabilities.
Latin America, Middle East & Africa:
These regions represent developing opportunities for drug repurposing. Improvements in healthcare infrastructure, increasing research investment, and growing awareness of unmet medical needs are expected to support market development. Repurposing may be particularly valuable for infectious diseases and conditions where access to newly developed therapies remains limited.
Key Players
Pfizer Inc.
Novartis AG
Bristol-Myers Squibb Company
Johnson & Johnson
AstraZeneca PLC
Eli Lilly and Company
Gilead Sciences, Inc.
Amgen Inc.
Teva Pharmaceutical Industries Ltd.
Sosei Group Corporation
Lantern Pharma, Inc.
Recursion Pharmaceuticals
Evotec SE
Charles River Laboratories
BenevolentAI
Market Research Future identifies pharmaceutical companies, biotechnology organizations, and specialized drug-discovery firms among the participants in the competitive landscape.
Future Outlook
The Drug Repurposing Market is expected to remain an important part of pharmaceutical innovation as companies search for faster, more economical approaches to therapeutic development. The combination of established drug safety information with AI, machine learning, real-world evidence, genomics, and large-scale biological datasets is likely to make the identification of new drug indications more systematic.
Artificial intelligence is expected to play an increasingly important role by helping researchers analyze complex relationships between compounds, disease pathways, molecular targets, and patient data. These tools could improve the ability to identify promising candidates earlier in the development process.
The market is also likely to benefit from increased collaboration between pharmaceutical companies, biotechnology firms, academic institutions, CROs, and technology providers. Such partnerships can provide access to specialized expertise and large datasets while reducing the burden on individual organizations.
Rare diseases, oncology, neurological disorders, and infectious diseases are expected to remain important areas of research. In addition, the growing use of real-world evidence may provide researchers with new ways to identify potential signals for existing medicines and support the development of new indications.
Overall, the future of drug repurposing will likely be shaped by the convergence of pharmaceutical science, data analytics, artificial intelligence, regulatory innovation, and collaborative research models. Market Research Future projects the global market to grow from approximately USD 39.2 billion in 2025 to USD 52.8 billion by 2035 at a CAGR of 3.1%.
Discover emerging opportunities with in-depth research reports:
Antimicrobial Coatings for Medical Devices Market Outlook
Anti-Inflammatory Therapeutics Market Analysis
